Stelara, J&J’s top-selling anti-inflammatory drug, brought in sales of $2.86 billion in the quarter, above LSEG estimates of $2.61 billion.
Tag Archive for: Johnson & Johnson
As the COVID-19 pandemic continues to recede, the top pharma companies intensified their focus into areas such as cancer and metabolic diseases to build up their pipelines, and their growth prospects, for the future.
J&J is heading into the remainder of 2023 with a new look and a revised outlook.
Johnson & Johnson’s nasal spray Spravato (esketamine) CIII outperformed extended-release quetiapine at inducing remission in patients with treatment-resistant depression, the company announced Wednesday at the same time the results were published in The New England Journal of Medicine.
A New Jersey appeals court on Tuesday threw out a $223.8 million verdict against Johnson & Johnson that a jury had awarded to four plaintiffs who claimed they developed cancer from being exposed to asbestos in the company’s talc powder products.
Global health aid agency Unitaid has written to Johnson & Johnson’s CEO Joaquin Duato, urging “immediate action” to expand access to the company’s tuberculosis drug bedaquiline, which is protected by patents hindering generic alternatives.
J&J’s therapy combination of antibody treatment Rybrevant and experimental drug lazertinib showed a clinically meaningful improvement in progression-free survival rate in patients.
Continuing its clinical win streak, AbbVie’s Skyrizi showed signs of superiority against Johnson & Johnson’s Stelara in topline data from a head-to-head Phase III Crohn’s disease study.
A medical researcher has asked a court to throw out a lawsuit that Johnson & Johnson filed against her over her 2019 study on the links between cosmetic talc products and cancer, saying that her research is sound and protected by free speech rights.
Data released today by AstraZeneca from a late-stage trial combining its blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer raises the bar for Johnson & Johnson’s rival treatment, analysts said.
